These peptides act by stimulating the release of insulin. The incretins GLP-1 and GIP are secreted from the small intestinal enteroendocrine L and K cells, respectively, and act on their target receptors present on the β-cells of the pancreas. The GLP-1 receptor (GLP-1R) and GIP ...
There is provided, inter alia, an aqueous solution composition comprising a GLP-1 receptor agonist as an active ingredient and multivalent anions having a charge of at least minus 2 as stabilising agent, wherein the total concentration of multivalent anions in the composition having a charge of ...
The glucagon-like peptide 1 receptor agonist (GLP-1RA) class of pharmaceuticals are highly effective agents for the treatment of T2D and for achieving weight loss.4-9GLP-1RAs have further been shown to reduce the risk of adverse cardiovascular outcomes in patients with obesity10and to contribute...
Furthermore, Exendin-4 treatment significantly diminished the TBI-induced overexpression of TNF伪 and IL-1尾, as well as phosphorylation of p38 and ERK1/2. These data suggest a strong beneficial action of the glucagon-like peptide-1 receptor agonist Exendin-4 in improving neurological outcomes by...
glucagon-like peptide-1 and glucosedependent insulinotropic polypeptide (GIP), which are both inactivated by dipeptidyl peptidase-4 (DPP-4). Those with type 2 diabetes may have a slowdown or stoppage of this process. However, using pharmaceutical doses of GLP-1 can restore insulin excretion. ...
Antonsen KK, Klausen MK, Brunchmann AS, le Dous N, Jensen ME, Miskowiak KW, et al. Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence: study protocol of a randomised, double-blinded, placebo-controlled clinical trial....
The glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital component of the G protein-coupled receptor (GPCR) family and is found primarily on the surfaces of various cell types within the human body. This receptor specifically interacts with GLP-1, a key hormone that pla...
Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with increased risks for gallbladder or biliary diseases, with a higher risk for GLP-1 RA use in weight loss, according to a review published online March 28 in JAMA Internal Medi
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have a beneficial weight-lowering effect in type 2 diabetes associated with a reduction incardiovascular mortality.116In the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial, ...
von Scholten BJ, Hansen TW, Goetze JP et al (2015) Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes. J Diabetes Complications 29:670-674Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on ...